1-8 of 8
Julhash U. Kazi
Close
Sort by
Journal Articles

Treatment Shapes Clonal Evolution and Resistance Patterns in Murine KMT2A -Rearranged Leukemia with Subclonal FLT3 N676K

Ton Falqués, Mattias Pilheden, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Axel Hyrenius Wittsten, Julhash U. Kazi, Anna Hagstroem-Andersson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3354.
https://doi.org/10.1182/blood-2021-144760
Published: 2021
Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2752.
https://doi.org/10.1182/blood-2019-129823
Published: 2019
Journal Articles

Tyrosine 842 Residue in the Activation Loop of FLT3-ITD Is Indespensible for Oncogenic Transformation

Julhash U. Kazi, PhD, Lars Rönnstrand, PhD
Journal: Blood
Blood (2016) 128 (22): 1561.
https://doi.org/10.1182/blood.V128.22.1561.1561
Published: 2016
Journal Articles

Loss of Src-like Adaptor Protein 2 Expression Increases the Transforming Potential of Oncogenic FLT3-ITD

Sausan A. Moharram, MS, Julhash U. Kazi, PhD, Lars Rönnstrand, PhD
Journal: Blood
Blood (2016) 128 (22): 5106.
https://doi.org/10.1182/blood.V128.22.5106.5106
Published: 2016
Journal Articles

Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia

Alissa Marhäll, PhD student, Thomas Fischer, MD, Florian H. Heidel, MD, Julhash U. Kazi, PhD, Lars Rönnstrand, PhD
Journal: Blood
Blood (2016) 128 (22): 5118.
https://doi.org/10.1182/blood.V128.22.5118.5118
Published: 2016
Journal Articles

Activating Mutations Are Potent Pro-Leukemic Mediators in Murine MLL-MLLT3 Leukemia That Cause Distinct Transcriptional Profiles

Axel Hyrenius-Wittsten, MSc, Helena Sturesson, PhD, Michael P. Walsh, PhD, Jenny Hansson, PhD, Julhash U. Kazi, PhD, Mattias Pilheden, MSc, Stephanie Nance, Pankaj Gupta, Guangchun Song, PhD, Jinghui Zhang, PhD, Jing Ma, PhD, Tanja A. Gruber, MD PhD, James R. Downing, MD PhD, Anna K. Andersson, PhD
Journal: Blood
Blood (2016) 128 (22): 3918.
https://doi.org/10.1182/blood.V128.22.3918.3918
Published: 2016
Journal Articles

Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Oscar Lindblad, Eugenio Cordero, Alexandre Puissant, Lucy Macaulay, Nuzhat N. Kabir, Jianmin Sun, Karin Haraldsson, Åke Borg, Fredrik Levander, Kimberly Stegmaier, MD, Kristian Pietras, Lars Ronnstrand, Julhash U. Kazi
Journal: Blood
Blood (2015) 126 (23): 2472.
https://doi.org/10.1182/blood.V126.23.2472.2472
Published: 2015
Journal Articles

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

De-Chen Lin, Tong Yin, Maya Koren-Michowitz, Ling-Wen Ding, Saskia Gueller, Sigal Gery, Takayuki Tabayashi, Ulla Bergholz, Julhash U. Kazi, Lars Rönnstrand, Carol Stocking, H. Phillip Koeffler
Journal: Blood
Blood (2012) 120 (16): 3310–3317.
https://doi.org/10.1182/blood-2011-10-388611
Published: 2012
Includes: Supplemental data